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ARTICLE
Current accounts of antimicrobial resistance:
stabilisation, individualisation and antibiotics as
infrastructure
Clare I.R. Chandler 1
ABSTRACT Antimicrobial resistance (AMR) is one of the latest issues to galvanise political
and ﬁnancial investment as an emerging global health threat. This paper explores the con-
struction of AMR as a problem, following three lines of analysis. First, an examination of some
of the ways in which AMR has become an object for action—through deﬁning, counting and
projecting it. Following Lakoff’s work on emerging infectious diseases, the paper illustrates
that while an ‘actuarial’ approach to AMR may be challenging to stabilise due to deﬁnitional
and logistical issues, it has been successfully stabilised through a ‘sentinel’ approach that
emphasises the threat of AMR. Second, the paper draws out a contrast between the way
AMR is formulated in terms of a problem of connectedness—a ‘One Health’ issue—and the
frequent solutions to AMR being focused on individual behaviour. The paper suggests that
AMR presents an opportunity to take seriously connections, scale and systems but that this
effort is undermined by the prevailing tendency to reduce health issues to matters for indi-
vidual responsibility. Third, the paper takes AMR as a moment of infrastructural inversion
(Bowker and Star) when antimicrobials and the work they do are rendered more visible. This
leads to the proposal of antibiotics as infrastructure—part of the woodwork that we take for
granted, and entangled with our ways of doing life, in particular modern life. These
explorations render visible the ways social, economic and political frames continue to deﬁne
AMR and how it may be acted upon, which opens up possibilities for reconﬁguring AMR
research and action.
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Introduction
‘Due to antimicrobial resistance, many achievements of the
twentieth century are being gravely challenged, in parti-
cular: the reduction in illness and death from infectious
diseases achieved through social and economic develop-
ment; access to health services and to quality, safe,
efﬁcacious and affordable medicines; hygiene, safe water
and sanitation; disease prevention in community and
health-care settings, including immunisation; nutrition
and healthy food; improvements in human and veterinary
medicine; and the introduction of new antimicrobial and
other medicines’ (Item 4, Draft Political Declaration on
AMR, United Nations General Assembly, 2016)
Reports of infections that are non-responsive to ﬁrst-lineantimicrobials have increased. Concern over resistance ofthe microbes causing these infections to the drugs used to
treat them has expanded as awareness of the absence of repla-
cement medicines has risen (Tripartite Collaboration on AMR,
2016). As the ﬁeld of antimicrobial resistance (AMR) research,
policy and action grows, what patterns of knowledge and ways of
knowing are shaping conceptual possibilities and boundaries? If
these systems of thought and knowledge are explicated, how
might the boundaries of these epistemes be pushed?
Sensitive to the controversy around the science of climate
change (Pearce et al., 2018), those engaged with AMR advocacy
have been careful to develop a ‘political narrative’ (Global Health
Security Agenda, 2016) that comprises consistent messaging and a
coherent voice within a science-policy complex. The collaboration
across the ‘tripartite’ of the World Health Organisation (WHO),
Food and Agriculture Organisation (FAO) and the World Orga-
nisation for Animal Health (OIE) has been commended as pro-
viding a platform for successful intervention across UN member
states (Inter Agency Coordination Group on AMR Consultation,
2018). An indicator of success of getting AMR onto the political
agenda was the high-level discussion of AMR at the United
Nations Global Assembly in 2016, resulting in a political
declaration (United Nations General Assembly, 2016), and the
appointment of an Inter-agency Coordination Group (IACG) on
AMR which seeks to generate a common direction across sectors,
industry and nations globally. This effort has been credited with
enabling strong global consensus on the problem of AMR and has
garnered political will to address the threat (Rochford et al., 2018).
Industry leaders in pharmaceuticals and diagnostics have become
partners in the ﬁght against AMR (Wellcome Trust, 2017),
articulated for example in a Davos declaration (AMR Industry
Alliance, 2016). The successful generation of this collective com-
mitment is said to hinge on the use of common language (Men-
delson et al., 2017) combined with a shared approach and set of
concerns (Inter Agency Coordination Group on AMR, 2017).
While AMR has been successfully established as a priority on
the global stage, AMR champions repeatedly voice concern over
the ‘implementation challenge’ of translating political commit-
ment into action (Wells et al., 2017, UK Department of Health,
2017). Thus far, standardised frameworks and tools are promoted
for country-level implementation, but ‘there is still much more
that needs to be done’ (Inoue and Minghui, 2017). Discourse
analysis can explicate to the way AMR has been stabilised and
mobilised as an object, can bring to the fore consequences of the
way the AMR problem has been framed, and can open up other
ways to attend to the constellation of issues represented by AMR.
Approach
In this paper I intend to bring to the fore aspects of the AMR
agenda that are taken for granted and deemed self-evident as
research, policy and action has been taking shape. The primary
inspiration for the approach is a Foucauldian discourse analysis,
through which the object of AMR is explored in how it is
represented and how it is practiced—treating discourse ‘as prac-
tices that systematically form the objects of which they speak’
(Foucault, 1972, p. 49). AMR might usefully be considered such
an object of discursive formation, contingent upon relations
‘between institutions, economic and social processes, behavioural
patterns, systems of norms, techniques, types of classiﬁcation,
modes of characterisation’ (p. 45). To trace AMR in this way then
develops analysis that understands it as an object that emerges in
relation to particular rationalities, juxtaposed with other objects
that deﬁne its difference.
Recognising the global nature of the AMR discourse, the
numerous institutions, connections and imperatives can be con-
sidered to comprise a ‘global assemblage’, hanging together under
the umbrella of AMR (Ong and Collier, 2005). In attending to
this emergent ‘thing’ of AMR, I follow the move to consider
diseases as socio-materially co-constructed entities, whose form is
enacted in multiple ways, inspired by the work of Mol (2002).
This sets the scene for my own understanding of what AMR is,
which is then built upon by observing the discourse in ‘the AMR
Community’ (an entity reiﬁed within the Community of scien-
tists, policy and public/global health practitioners) through ana-
lytical lenses borrowed principally from Lakoff (2017), Rose
(2001) and Bowker and Star (2000).
Through this analysis, I present three current accounts of
antimicrobial resistance (AMR) as it has emerged in relation to
particular priorities and formulations of science and policy. First,
I focus on the challenges of stabilising AMR as an object through
traditional deﬁnitions and counting, and explore the way that
projection of AMR as a threat seems to have been more effective
for stabilising this object. Second, I juxtapose two core features of
the AMR risk discourse—the One Health paradigm, and the
behavioural model of intervention—drawing attention to a
paradox in AMR as a problem of connectedness to be solved by
individualised action. Third, I develop an account of AMR that
conceives of antibiotics as infrastructure, opening-up alternative
paths for exploring this emergent ﬁeld.
The analysis draws from a range of material that includes
published scientiﬁc and policy literature, scientiﬁc conference
presentations and interviews and discussions with scientists and
policy makers. The analysis is informed by my own immersion in
the ﬁeld of AMR science and policy, as a researcher and as co-
Director of the AMR Centre at the London School of Hygiene &
Tropical Medicine.
Ethical approval for the ﬁeldwork in this study was granted by
the LSHTM Observational Ethics Committee, reference numbers
11598 and 15244.
Stabilising antimicrobial resistance as a threat
‘There is a gesture often used to describe the antimicrobial
resistance (AMR) problem—an inﬂection of the hand
tracing a curve like the up-side of a mountain. At a meeting
of scientists, a journalist asks, ‘How afraid should we be of
AMR?’. This gesture provides the answer. At an AMR
policy event, a civil servant is making the case for
investment in AMR, he makes the gesture. I ask a medical
doctor in a low-income country, ‘what is your experience of
AMR where you practice?’. The same gesture. I see it
repeating in settings of science, policy and practice around
the globe. I can’t ﬁnd the curve drawn out in the scientiﬁc
literature, but we have a shared understanding that this is
the shape of the curve. The gesture stands in place of data,
communicating the need for response. It mirrors the
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‘hockey stick curve’ deployed in the 2014–2015 Ebola
response (Kelly, 2018), implicitly connecting the two crises.
How has this shared understanding of the AMR threat been
brought into being?’
Fieldnotes London 15 and East Africa 12, 2018
Lakoff (2015, 2017) proposes the concept of the ‘sentinel
device’ to describe the way that public health threats have come to
be responded to—requiring vigilant attention and speculative
intervention for a surprise and potentially catastrophic event. He
contrasts this with the more established ‘actuarial’ style of rea-
soning that justiﬁes action through the statistical calculation of
risk, projecting the past into the future. Actuarial devices work in
a world where threats can become known through accumulation
of epidemiological risk data and application of cost-effectiveness
analyses to guide intervention. By contrast, sentinel devices work
in a world where a dangerous future cannot be known through
calculation and a precautionary mode is required to guide
intervention. Observing the way topics in global health now often
follow the speculative turn in ﬁnance, hedging on ‘potential’
rather than ‘likely’ events, affects the orientation of action
including ﬂows of both public and private ﬁnance. In each case, a
distinct set of logics connects through particular modelling
approaches that render ﬁnancial, health and other (see also dis-
aster and development discourses) paths for action more, and
less, inevitable.
Here I will explore the way that the actuarial approach to AMR
continues to be a strong part of AMR research and imple-
mentation agendas—to come to know where AMR is, how much
there is and points for control—but that the deﬁnitional and
technical challenges inherent to this complex category mean that
this is challenging to stabilise as an object through this lens. By
applying the logic of the sentinel, or speculative, device, it
becomes possible to see how AMR has become stabilised on the
global stage as a threat, and rendered amenable to particular
forms of action—and investment.
The actuarial approach: deﬁning and counting AMR. Histories
of AMR identify waves of political enthusiasm in the topic. The
troughs between the waves have been attributed to complacency
(Podolsky, 2018) but also to the complexity of the challenge of
understanding and responding to this biologically inevitable and
remarkably diverse issue (Wells et al., 2017). Attempts to stabilise
AMR through actuarial accounts, in order to act upon it as an
issue, have been challenged by difﬁculties in deﬁning what AMR
is, and in being able to count it.
Although AMR is a commonly used term, it is not easy to
create a common deﬁnition. Broadly, it is used to describe a
phenomenon of microbial organisms becoming less susceptible to
the antimicrobial medicines used to eliminate or control them.
This phenomenon is described in bacteria, fungi, parasites and
viruses (see, e.g., Fisher et al., 2018; Dondorp et al., 2009;
Keshavjee and Farmer, 2012; Laxminarayan et al., 2013; Baggaley
et al., 2010). Amongst bacteria alone, the term AMR describes a
wide range of species and strains which develop or acquire
different characteristics that render medicines less effective.
Mechanisms described as conferring antibiotic resistance vary
widely, including enzyme production that inactivates the drug;
modiﬁcation of drug targets sites, preventing binding; reduction
of permeability to the drug; production of alternative metabolic
pathways that bypass the drug’s target pathway; and the use of
various pumps to export antibiotics or prevent the drug from
reaching a bacterial intracellular target (Kapoor et al., 2017). A
given bacteria may have evolved a resistance mechanism or may
have acquired it through transfer of genetic material from another
bacteria of the same or even another species (Gillings, 2017).
When an antibiotic is unable to act upon a bacteria because of
that organism’s physical characteristics, this is also termed
resistance, this time ‘intrinsic’ (Neu, 1992). The term AMR
therefore accommodates a variety of microbial and genetic
activity, even just within bacterial AMR. Similarly there are
numerous registers for recognising AMR. Clinically, AMR may be
recognised if a patient’s infection does not clear after an antibiotic
expected to impact that infection is taken. Microbiologically,
AMR may be recognised if bacteria that are grown from a sample
and plated on agar in a laboratory are unaffected when an
antibiotic is introduced. Molecularly, AMR may be recognised
from the presence of a genetic sequence that has previously been
typed as conferring drug resistance may be identiﬁed in a
bacterial sample, or in a faecal, soil, water or other sample. And
the ways we have come to understand resistance have evolved
together with laboratory technology (Gradmann, 2013). When we
talk of increasing resistance, then, we may be referring to an
increase in clinical cases that are hard to treat, increase in
identiﬁcation of a particular bacteria with resistance to a
particular drug, a bacteria resistant to a particular group of
similar action drugs, a bacteria resistant to a range of drug types,
or an increase in identiﬁcation of a particular piece of genetic
material. To complicate things further, carriage of any of these
bacteria may or may not cause disease in the short or long term
for the human carrier. And the existence of such bacteria in the
metabiome—matter outside of humans—may also be ‘friendly’ or
not. Therefore, while bacteria with a particular ability to resist
particular antibiotics may be common in a given context, the
frequency of infection caused by such bacteria may be low
(Stenehjem and Rimland, 2013). Finally, while a bug may be
resistant to a particular drug, it may be responsive to other drugs,
requiring categories of ‘extremely drug resistant’ and ‘pan
resistant’ infections.
The above description demonstrates the multiplicity of AMR
(Mol, 2002); deﬁnitions of AMR could be as numerous as drug-
bug combinations exist, articulated in clinical, microbiological
and molecular registers. Nonetheless, AMR needs to be counted
in order to demonstrate its relative importance (Adams, 2016). A
key commitment from UN Member states has been to set up
surveillance on AMR. Once AMR can be counted then it is
possible to account for action upon it. This mirrors Foucault’s
proposition of the role of statistics in shaping public health
(Foucault, 2008). Currently, however there is limited data on
AMR—in any of its possible deﬁnitions—outside of well-
resourced tertiary care settings or research studies. The WHO
(2017) AMR surveillance report demonstrated the paucity of data
around the globe that count AMR (World Health Organization,
2017). It also demonstrated the heterogeneity in what is captured
between countries under AMR. The multiplicity within the term
AMR may explain why it has been difﬁcult to deﬁne indicators to
capture its prevalence in a meaningful way across species,
medicines and settings. Existing surveillance systems typically
collate microbiology data of isolates from hospital patients. A key
challenge in counting AMR is to expand such surveillance
globally, and beyond the hospital setting. At the moment,
estimates of the AMR burden in LMICs is derived through a
series of extrapolations—for example the proportion of neonatal
sepsis deaths attributable to drug resistant infection, estimated as
214,500 in 2012, based on an expected proportion of all neonatal
deaths attributable to severe infection, and of those, attributable
to a drug resistant infection to the ﬁrst line treatment
(Laxminarayan et al., 2016). Even with planned investment in
laboratory capacity for microbiology, from the UK’s Fleming
Fund, the US Centres for Disease Control and others, surveillance
is unlikely to expand beyond a reference site model in most low
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resource settings (Seale et al., 2017), leaving population levels of
AMR, and clinical impact of drug resistance relatively unknown.
The scale of the AMR problem is inferred rather than known,
even in relatively high resource settings. In the US, around 25,000
excess deaths have been associated with AMR yearly, but even
there it is accepted that ‘such estimates depend heavily on the
type of included infections and resistance mechanisms, and the
extrapolating techniques used’. (Pires et al., 2017). When looking
at ﬁnely grained patient data, a review of 15 years of data from
2001 in Marseille, France, found that extremely drug resistant
bacteria—where bacteria were resistant to more than two
antibiotics—were uncommon (37 of 27,681 inpatient bacterial
infections) and of these cases four cases died, three attributable to
other causes (Abat et al., 2017). However, the stark contrast in
incidence of infection between this setting and many LMICs
leaves the question open as to transferability of these ﬁndings
across settings.
Generating capacity for AMR surveillance is a clear priority.
However, this will take substantial time, and resources. Predicting
the course of AMR is argued as key to prepare for the potential
crisis. Even with good data, however, the trajectory of resistance
has been shown to be non-linear, dependent on drug-bug
combination but also context. When the Marseille group
reviewed hospital data over 15 years from 2001 to look at trends
in AMR (Abat et al., 2017), they found that MRSA actually
decreased, and there were no changes in levels of vancomycin or
imipenem resistance in clinically important bacteria. With
antibiotic stewardship, drug resistant infection has been found
to decrease in some hospital settings (Baur et al., 2017), although
the relationship is not always so clear, as susceptibility does not
always rebound after drug pressure is reduced (Burke, 1998).
Thus, the future direction of ‘AMR’ as a collective category is
hard to predict on a granular level.
In summary, stabilising AMR through actuarial accounts has
been met with deﬁnitional, technical and resource challenges. In
the places where we do have ﬁgures, they are relatively small
compared with other health concerns. In order to propel AMR to
a global political stage, and to compete with other disease that
have gained attention and funding on a large scale, AMR has
required a different form of articulation.
The sentinel approach: projecting AMR. We have seen that
AMR is difﬁcult to deﬁne in the singular; the phenomenon
captures multiple processes, bugs and drugs. We have also seen
that it is difﬁcult to count, both because of its multiplicity and due
to resource and technical limitations. Nonetheless, it has been
possible to evoke projections of AMR—of what it might be—and
therefore to stabilise it as a threat in the future tense, that must be
acted upon in anticipation.
An increasing number of public, private and multilateral
institutions have now published reports on AMR. A familiar
structure can be observed in each, through which AMR is
described as a major health threat, driven by antibiotic overuse,
and a description of the consequences of AMR and set of
solutions is then outlined. Quantiﬁcation of the current scale or
nature of the AMR problem is notably absent; reports allude to
the ‘lack of data’ whilst emphasising a ‘certain threat’. The UK
Government-commissioned O’Neill Review on AMR provided a
projection that, if left unchecked, 10 million people would die per
year from AMR by 2050 (O’Neill, 2014). While the science
behind these ﬁgures has been contested (de Kraker et al., 2016),
and many openly recognise the ﬁgures as of more political than
scientiﬁc value, the ﬁgures have been widely used across science
and policy, including as ‘underestimates’. In their follow-up book,
O’Neill and colleagues provide images of the shape of the curve
that AMR impact could take into the future – although this is in
economic rather than morbidity or mortality terms (Hall et al.,
2018). The authors echo a dominant sentiment in the ﬁeld that
‘we should always try to improve predictions but we should take
action now.’ This sentiment of the need for action regardless of
the accuracy of the threat is common across AMR discourse, for
example when arguing for more investment into AMR monitor-
ing architecture, Wernli et al. (2017) state that ‘While the long-
term impact of AMR on human societies remains uncertain, the
conservation of antimicrobials’ effectiveness has become an
urgent priority’ (p. 1).
The way AMR is framed as a threat, a potential catastrophe,
echoes the nature of other pandemic threats in recent times. The
discourse is remarkably similar in form to that of pandemic
inﬂuenza (Caduff, 2015) as well as SARS, Zika (Lakoff, 2017) and
Ebola (Kelly, 2018). Where AMR is described as a ‘growing
spectre’ (Talkington, 2017), H1N1 was described as a ‘killer strain
lurking in the shadows.’ Caduff (2015) observes that a key aspect
of framing disease as a threat is the generation of a ‘public culture
of danger’, through which he argues subjects of liberal rule are
systematically reminded that life is under threat; and, following
Foucault (2008), that the fear of such existential threat ‘is at the
heart of the modern social contract and the formation of modern
political communities’ (Caduff, 2015, p. 189). The resulting
anticipatory affect can be understood as part of practices of
making futures present—by formulating life as contingent,
subject to future surprises, forms of pre-emption and pre-
mediation are required as anticipatory action (Anderson, 2010;
Cooper, 2006).
As well as the threat of AMR forming a biopolitical project
through looming health crisis, an area that has been particularly
developed as a threat in AMR compared with other pandemics is
the impact on economies. Foregrounded here are the potential
economic costs of AMR to health and healthcare in given future
scenarios. While earlier economic forecasts found the additional
costs associated with AMR compared with susceptible infections
to be relatively small (Smith and Coast, 2012), more recent
estimates are substantially larger, drawing on a different set of
assumptions. As Bruce Braun has reﬂected, the shift from
calculable disease risks to anticipation of potential or ‘virtual’
events brings challenges for planning; he asks ‘how does one
bring the ‘unspeciﬁable’ future-to-come within the realm of
economic and political calculation? By deﬁnition the virtual is
incalculable.’ (Braun, 2007, p. 19). In AMR, a way forward was
forged by British economists engaged in producing cost-impact
estimates for AMR, Richard Smith and Jo Coast, who wrote in
2012 that ‘the cost of resistance needs to be high now to justify
greater restriction on use of current drugs’ (Smith and Coast,
2012, p. 8), and further argued that estimates ‘must encompass
the costs that might relate to the loss of modern healthcare’
(Smith and Coast, 2013, p. 2). Their example case of hip
replacements as an example of the multiple points at which AMR
could cost the health system has been adopted widely to illustrate
the potential catastrophic costs of AMR (European Commission,
2016; World Health Organisation, 2016; Department for Health,
2013). The authors go further to ‘speculate’ about the impact on
productivity and wider societal costs, proposing that to include
these costs, and a scenario where no antibiotics work, would allow
estimation of ‘the full potential economic costs’ (sic). They argue
that ‘rather than see expenditure on antimicrobial policies as a
cost, we should think of it as an insurance policy against a
catastrophe; albeit one which we hope will never happen’ (ibid. p.
2). Thus, the criteria for economic costing was widened
considerably, although also with considerable uncertainty. When
the O’Neill report authors commissioned teams from KPMG and
RAND Europe to calculate worldwide estimates of the impact of
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AMR, they followed the principles of this model, resulting in
projections of cumulative cost to global economic output of 100
trillion USD by 2050 if no action is taken (O’Neill, 2016).
Following the O’Neill Report, in 2017 the World Bank published
a report on Drug Resistant Infection with the subtitle ‘A threat to
our economic future.’ The report is based on economic
simulation tools and provides a vision of ‘AMR’s destructive
impacts on the global economy… if adequate measures aren’t
taken to contain the AMR threat.’ The report’s executive
summary emphasises that ‘putting resources into AMR contain-
ment now is one of the highest-yield investments countries can
make’ (World Bank Group, 2017). This rhetoric echoes the policy
rhetoric that ‘we cannot afford to return to a pre-antibiotic era’
(Tripartite Collaboration on AMR, 2016).
The emphasis on investment in health issues on a global scale
is not new or unique to AMR. It is an emphasis that has shifted
the shape of international health efforts since Rockefeller applied
his business models to his Foundation, most notably in the
investment into countries to support malaria control (Eckl, 2014).
However, the application of the models used in the now
dominant form of investment—hedge funds—to health is
relatively recent. Thus, not only is the principle of supporting
other countries’ health issues seen as an investment with return
for the supporting country, but the mathematical models and
assumptions that go along with investments into speculative
futures are also being applied. George Osborne, UK Chancellor of
the Exchequer under David Cameron’s Prime Ministership, is
quoted in O’Neill’s Superbugs book as saying, ‘there is a growing
recognition of the ﬁnancial costs of failing to tackle antimicrobial
resistance and the need for ﬁnancial expertise in developing the
solution.’ (Hall et al., 2018, p. 52). Encouraged by the desire for
funding technological solutions to AMR venture capitalists in the
AMR space are identifying ‘opportunities’ for investment. One
major opportunity is for diagnostic testing, with a potentially
global market for tests for surveillance and treatment. Thus, the
‘sentinel’ approach to disease surveillance emerges where we
invest in vigilance and speculative future events (Anderson,
2010), ﬂuently incorporating both the language and the capital of
the current ﬁnancial sector’s models. Emerging from these
models are forecasts that can be hedged upon, and with the
emphasis on technological development as a solution to AMR,
private investors are able to anticipate different potential futures
upon which they may place options.
The language of a ‘sentinel’ approach also reminds us of the
securitised nature of the AMR phenomenon. The projections of
and preparedness for threats stand to protect publics from danger
(Caduff, 2015). This danger in AMR is often personiﬁed in the
form of ‘superbugs’ with which we are to wage war (Nerlich,
2009). An increasingly popular approach, also borrowed from
war, when preparing for health crises and disaster management is
simulation (Lakoff, 2007). Deployed in the 1980s for Ebola ‘war
games’ (Garrett, 1994), simulations have since been used as
modes of preparing for potential pandemics such as smallpox,
anthrax and avian inﬂuenza (Lakoff, 2007), and are common in
preparing for zoonotic disease outbreaks both in high income
settings (Keck, 2018) and in national programmes for example in
Uganda’s ‘One Health Strategic Plan’ (Republic of Uganda, 2018).
Lakoff (2007) has drawn attention to the way priorities and
resources are re-designated as a result of simulations, ‘by making
infrastructural vulnerabilities visible’ (p. 266). Frédéric Keck
(2018) has argued that, as well as operating as pastoral techniques
of power, we can also understand the work done through these
simulations as ‘cynegetic’, building in uncertainty at the borders
between species (p. 15). As simulation exercises begin on the
topic of AMR, for example at the G20 meeting in Argentina in
October 2018 (see, e.g., Department for Health and Social Care,
2018), these efforts seem at this point to orientate simulation
more as a discussion and galvanising tool, to re-emphasise
threats, which at once opens up the uncertainty and potential
catastrophic scale of AMR, and at the same time creates certainty
in reinforcing messages that action is required now.
Finally, it can already be observed that AMR is understood as a
threat not only to health, to economies, to security, but also to
modernity itself. Statements that AMR could hail the end of
modern medicine echo through the media, and are common in
speeches at both policy and research events. For example, at the
UK House of Commons Enquiry into AMR, the Chief Medical
Ofﬁcer warned that ‘We will lose modern medicine’, the ability to
undertake major surgery, cancer treatment and transplants,
‘There will be a lot of suffering and modern medicine will be
lost’ (House of Commons, 2018, p. 3). At stake are many of the
ways we care for our bodies, ways that we have invested in and
developed infrastructure to support in the modern era. The
potential loss of antimicrobial efﬁcacy also represents a less-
vocalised threat to modernity beyond health care—to our modes
of production which we become increasingly aware are reliant on
antimicrobials. Thus the ﬁght against AMR can be read as much
as a ﬁght for modernity.
Therefore, when AMR is presented as one of the most pressing
global threats—articulated in terms of a threat to health,
economies, security and modernity—we see bound together a
classic biopolitical phenomenon in a neoliberal framework. So
that despite the ambiguity of the AMR concept, and our lack of
‘actuarial’ knowledge of its current scale or future impact, an
imperative to act on AMR has become clear. Just as we saw with
the spectre of avian inﬂuenza (Davis, 2005), the communities of
practice emerging around the policy-science-industry nexus
relating to AMR, and the consequent multilateral statements
and commitments, are testament to the effective construction of
AMR as an object that it is agreed must be acted upon.
A problem of connectedness; individualised solutions.
‘People need to be brought on-board, so we are together in
the one health approach’ I hear from an East African civil
servant, ‘but implementation is a challenge with irrational
use of drugs by villagers’. The rhetoric of a One Health
approach, accompanied by frustration at human behaviour,
echoes many conversations and consultations I’ve engaged
in with experts and policy makers about the intractability of
the AMR problem. What is the relationship between these
two conceptualisations?
Fieldnotes East Africa 18, 2018
In the previous section we have seen that AMR has been
stabilised as an object in the form of a threat, and that this has
been important for galvanising support—‘Why we need to act
now: We cannot afford to return to a pre-antibiotic era’
(Tripartite Collaboration on AMR, 2016). We have also seen
the concern that political commitment should be translated into
implementation—‘only 5% of countries have a multisectoral
AMR action plan that has been implemented with identiﬁed
funding sources and monitoring processes in place’ (Wellcome
Trust, 2016a). In this section, I explore two frameworks for action
that are prominent in global discourse. The ﬁrst is the narrative
that explains AMR as a One Health problem, building a growing
number of sectors into the deﬁnition of the problem, and
therefore as points to locate solutions. The second is recourse to
established rhetoric and instruments of behaviour change for
formulating solutions. While the ﬁrst strengthens new paths of
connection between sectors, between humans and ‘nature’, and
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between the local and the global, I argue that the second obscures
this understanding of connectedness by foregrounding individual
responsibility for the AMR phenomenon.
One health: AMR as a problem of connection. Today, addres-
sing AMR is often described as requiring a ‘One Health’ approach
—typically deﬁned as ‘multisectoral’ (World Health Organisation,
2015). This means understanding drivers of AMR as located
within and between agricultural, human health and environ-
mental domains. Diagrams illustrate the emergence and circula-
tion of drug resistant bacteria through livestock, food, water,
hospitals, people, sewerage and so on, as shown in Fig. 1 (see also,
e.g., Coutinho et al., 2013; Walsh, 2018) as well as showing the
ﬂow of antimicrobial drugs through these same channels (see,
e.g., BioMerieux ﬁgure ‘The Spread of Antibiotic Resistance’
(accessed October 2018)). These illustrations emphasise the many
points of connection within particular ecosystems that can be
understood to increase risks of AMR.
The One Health approach to AMR also promotes interdisci-
plinary collaboration (European Commission, 2017; UK Govern-
ment, 2013). Developments in the science of AMR allow us to
understand how resistance travels between microbes, and we have
become increasing attuned to microbial ecologies through
concepts such as the microbiome, evoking a heightened sense
of interconnectedness between humans and the natural world
(Landecker, 2016). Therefore, whilst rhetoric that utilises
metaphors of war implies an ‘us’ and ‘them’ in ﬁghting resistant
bacteria, the One Health framing draws together an imagery that
begins to depart from classic formulations of infectious disease
control. For much of the enlightened scientiﬁc era, our imagery of
infectious disease has relied on compartmentalism of human,
animal, insect and environmental realms. Characterised by linear
arrows and cyclical feedback loops, infection of humans is
depicted in terms of pathogens traversing these realms. In this
perspective, humans are considered separate (and separable) from
the ‘natural’ reservoirs of infectious disease (Lynteris, 2017).
Through apparatus such as DDT, extermination, physical
barriers, characteristic of ‘hygienic modernity’ (Rogaski, 2004),
we were able to visualise a disease-free humanity separated from
nature (Lynteris, 2016). Research in a One Health framework
does begin to question these imagined boundaries, with new ways
of understanding infection, such as ‘folded’ life (Hinchliffe and
Ward, 2014). As people struggle to capture the intricacies of AMR
with a One Health approach, diagrams become ever more
complex, and it becomes clear that depictions of arrows, drivers,
factors, as linear processes of infection from the outside in,
become increasingly insufﬁcient to account for AMR in the
context of these dissolved boundaries.
A One Health approach to AMR often also incorporates ‘One
World’, reﬂecting the global nature of the problem with
connections through food systems and human travel (Robinson
et al., 2016). We often hear and read that ‘AMR does not respect
borders’ (Wellcome Trust, 2016a; World Health Organisation,
2018a). In an article posted on 10 October 2017, the Pew
Charitable Trusts released an animated map showing the global
spread of resistance gene ‘New Delhi metallobeta-lactamase 1’ or
Fig. 1 Antimicrobial Resistance in the Food Chain infographic from WHO. This ﬁgure is covered by the Creative Commons Attribution 4.0 International
License. Reproduced with permission of World Health Organisation from “Infographics: Antibiotics in the Food Chain. WHO list of critically important
antimicrobials (WHO CIA list)—5th revision” https://www.who.int/foodsafety/areas_work/antimicrobial-resistance/AMR-food-chain-infographics/en/
Copyright © WHO (2017), all rights reserved
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‘NDM-1’ (Talkington, 2017). Tracking the publications of
ﬁndings of this gene from 2006 to 2015, the animation colours
in the greyed-out map as years progress—ﬁrst India becomes red,
then a series of other countries each year, until in 2015 there are
80 red countries. The accompanying commentary remarks,
‘These outbreaks are a sobering reminder that when antibiotic
resistance develops anywhere, it is a threat to people everywhere.’
(ibid). Another recent example raising concerns of the spread of
an emergent resistant gene is ‘mobilised colistin resistance 1’ or
‘MCR-1’, identiﬁed in pigs and humans in China in 2011 and
subsequently identiﬁed in countries across ﬁve continents (Wang
et al., 2018).
While the One Health approach to AMR mainly focuses on
drawing attention to interconnectedness between domains—
whether sectoral, disciplinary or countries—it also has allowed
for analyses of reasons for the emergence of AMR, drawing
attention to the ways we connect with each other and with nature.
The relationships between antimicrobial use and resistance remain
mysterious, with analyses suggesting a weak link for some drug-
bug combinations at both a macro and micro level (Collignon
et al., 2018; Caudell et al., 2018). Nonetheless, there is an increasing
understanding of AMR as an anthropogenic problem, a con-
sequence of our collective reliance on antibiotics (Lee and
Motzkau, 2013). Such a perspective is palpable in the mainstream,
following the path paved by climate change (ibid). For example in
their call for a global governance framework, participants from a
Leeds Castle meeting in 2018 led by Dame Sally Davies note that,
‘The emergence of resistance is a natural phenomenon but is
accelerated by a complex combination of human activity in health
care, agriculture (including animal husbandry, aquaculture, and
crops), and environmental contamination’ (Rochford et al., 2018,
p. 1977). Thus, we begin to see sensitivity to material-biotic
interdependencies emerging in global level discourse, and we see
the framing of One Health being mobilised to encompass
numerous registers of connectedness in understanding AMR. To
a degree, this suggests a move towards understanding health as no
longer bounded and separable from other arenas of economics and
politics, and humans as no longer separable from nature. This can
also be understood in relation to the ‘sentinel’ model described
above, in which bodies are imagined as at risk of surprise
pathogenic attacks in a chaotic and unpredictable molecular world,
as Braun observes, ‘a body understood in terms of a general
economy of exchange and circulation, haunted by the spectre of
newly emerging or still unspeciﬁable risks’ (2007, p. 15).
Behaviour change: individualised solutions. Given this rhetoric
of AMR as a One Health issue, advocating for recognition of
complexity and connectedness that requires a multi-sectoral
response, it is curious then to observe that the behaviour change
of individuals is so frequently cited as a key solution to AMR. For
example, Public Health England’s Keep Antibiotics Working cam-
paign speciﬁcally ‘focuses on the personal risks of antibiotic
resistance’ in an attempt to reduce demand for antibiotic pre-
scriptions from doctors (Public Health England, 2017). Behavioural
targets are primarily reduction of antibiotic use by patients, pre-
scribers and farmers to reduce drug pressure on microbial popu-
lations, and handwashing and allied hygiene behaviours to prevent
the spread of AMR. The upsurge in interest in AMR has revitalised
the rational prescribing movement, energised by the behavioural
economics models (Rynkiewich, 2018) that are increasingly inﬂu-
ential in social policy in the UK and US to ‘nudge’ people to ‘do the
right thing’ (Matjasko et al., 2016). There is now increasing interest
in WASH (water, sanitation and hygiene) and ‘biosecurity’ beha-
viours in the human and animal health domains, respectively. For
both antimicrobial use and hygiene interventions, there is
increasing recognition that existing evidence base is unable to
provide conﬁdence in guiding effective and cost-efﬁcient action.
Several reviews have now underlined the ‘mixed results’ of eva-
luations that are unable to identify a desired recipe for successful
behavioural interventions on antimicrobial use (Price et al., 2018;
Davey et al., 2017; Arnold and Straus, 2005; Van Dijck et al., 2018).
Nonetheless, the precautionary principle, a concept that relates to
the sentinel approach explored above, requires action now, while
further research is commissioned to hone in on the best ways to
change behaviour.
Current interventions for reducing antimicrobial use revolve
around raising awareness and what is now widely referred to as
‘stewardship’. Campaigns and programmes orientate around
individuals realising their responsibility to prevent a future
tragedy that may occur due to their unnecessary use of
antimicrobials today. Thus, materials are often designed to
communicate risk, linking the future to actions today. For
example, ‘Misuse of Antibiotics puts us all at risk’ (Fig. 2, WHO,
2017). And materials communicate the choice that an individual
has—e.g., the choice of an individual to take a pill like they might
take a sweet (Fig. 2). The premise of such communication
includes not only that the audience is ignorant of the topic, but
also that the reasons for their behaviour emanates from a position
of choice. They could choose not to, as easily as choosing not to
eat a sweet. Not only does this fall into the common trap of
isolating behaviour from context (the reasons for taking or
prescribing an antibiotics are invariably dependent upon non-
behavioural factors, and are often beyond the control of
individual patients or prescribers—(see, e.g., Haenssgen et al.,
2018; Pearson and Chandler, 2019)) but it also imagines that
taking antibiotic medicines is a decision that is taken as
unthinkingly as eating confectionary.
Underlying these behaviour change models—both in the
antimicrobial stewardship and hygiene domains—is the assump-
tion that action is instigated by cognitive or habitual functions of
individuals. Moreover, it is often assumed that existing practices
are rooted in erroneous beliefs or problematic culture that require
intervention (Haddad, 2016). The focus on individuals as targets
of interventions for change can be understood as part of a liberal
framework that tends to locate risk and responsibility at the level
of citizens (Petryna et al., 2006). Following in the footsteps of
‘lifestyle choices’ as a framing that recast responsibility towards
individuals and away from the state (Lupton, 1995), at home in
the rhetoric of choice (Mol, 2008) and self-improvement (Türken
et al., 2016), and resonant with the logics of global health metrics
and accountability (Adams, 2016) the thrust towards ‘behaviour’
in AMR interventions allows for deviant individuals to come into
view as amenable to evaluable intervention while expectations
from the state are obscured as unfeasible and idealistic. Political
and infrastructural issues, that the One Health framework would
indicate are likely to underlie AMR risk, are cast as ‘complex’ and
‘not amenable to change’, to be circumvented with simple
technologies as repeatedly observed in global health (Street, 2012;
Beisel et al., 2016).
Thus, while a review on country AMR progress by the WHO
(2018b) notes ‘The necessary changes to global antimicrobial
use exceed what can be achieved using individually targeted
behaviour change strategies’ (p. 3), the report goes on to
emphasise the need for progress ‘as most countries have not yet
launched nationwide, government supported campaigns on
AMR awareness in human health, nor have they implemented
strategies to change behaviour regarding AMR in target groups
in human health’ (p. 12). Taking together the uncertainty in the
evidence base of behaviour-oriented interventions, and the
evidence used to build the One Health argument that suggests
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AMR as a systemic issue of connectedness, rather than
individuals, one might expect an increase in activity and
research to address ‘structural’ level issues that shape possibi-
lities for action at a local level. This is occurring to a certain
degree, with an ongoing review of governance interventions
(Rogers Van Katwyk et al., 2017) and for example through the
Wellcome Trust’s (2016b) proposal for ‘enhanced ‘gating’ of
antibiotics, ‘so more use is routed through healthcare profes-
sionals and over-the-counter use is minimised’ (p. 2). Although
such proposals are challenging to negotiate given parallel
concerns around access to lifesaving antimicrobial drugs
(Laxminarayan et al., 2016), such concerns might equally be
applied to individual-oriented interventions (see, e.g., the
unintended consequences of malaria rapid diagnostic tests on
access to antimalarials (Hutchinson et al., 2017a, 2017b)).
Nonetheless, analysis of current discourse suggests most often a
doubling-down on the individual; following the pastoral model
of biopolitics characterised by Rose (2001) and which stands in
contrast to the securitised form of geopolitics described in the
One Health framework (Braun, 2007). Adding to the ongoing
focus on cognitive interventions, there is increasing interest in
targeting affect or emotion for behaviour change. For example,
in a review on hand hygiene interventions, Wilson et al. (2011)
propose that ‘interventions that provoke emotive sensations
(e.g., discomfort, disgust) or use social marketing may be the
most effective’ (p. 119). Similarly, a review on the nature of
mass media campaigns on AMR concludes that ‘further
research is needed to systematically illuminate and capitalise
upon the use of affect to effect behaviour change concerning
antimicrobial stewardship.’ (Langdridge et al., 2019).
Antibiotics as Infrastructure.
There is a recipe for the rapid growth of pig and chicken
farming in Uganda: smaller spaces, larger imported breeds,
intensive cleaning, imported feed concentrates, and anti-
biotics. ‘I use a lot of medicines, including antibiotics',
explains a middle-aged gentleman who like many others is
new to farming, having left employment in the civil service.
‘If I do not, then I cannot make a proﬁt'. He and his fellow
farmers describe how the recent push to commercial rather
than subsistence farming reﬂects a number of societal shifts.
There is liberalisation, which they say means that they as
members of the population now shoulder greater risks—
and potential rewards—with commercialised farming
models. Then there is modernisation, which they explain
increases demand for eggs, chicken and pork, ‘so there is a
push to enhance how much your chicken can produce'.
Then there is standardisation, whereby a particular sized
chicken is given a set price on the market, and if you can
produce it in 4 rather than 6 weeks then you can get an
edge on balancing your books. In each case, we learn that
antibiotics play an important but often invisible role.
Fieldnotes East Africa 152, 2018
German scientist and Nobel laureate Paul Ehrlich used the
term Zauberkugel (Ehrlich, 1913), or ‘magic bullets’, to refer to
substances that could kill disease-causing microbes without
harming the host. The term captures the imagination as an ideal
targeted intervention, drawing attention to the effectiveness
rather than the effects of these magical substances. Unwanted
Fig. 2 WHO Poster for World Antibiotic Awareness Week (2017). This ﬁgure is covered by the Creative Commons Attribution 4.0 International License.
Reproduced with permission of World Health Organisation from ‘World Antibiotic Awareness Week 13–19 November 2017' https://www.who.int/
campaigns/world-antibiotic-awareness-week/2017/posters/en/ Copyright © WHO (2017), all rights reserved
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effects blur out of focus. They are ‘side’ effects, mundane and
uninteresting in contrast with the magic of high efﬁcacy. Whilst
retaining their mystique and desire as powerful substances, the
mass production of antimicrobials and possibilities they pre-
sented rapidly moved them into the fabric of lives and healthcare
systems around the world (Podolsky, 2015). Antimicrobials were
soon seen as essential to human life, with access to these
medicines enshrined as primary health care in the declaration
signed by 134 countries from around the world at Alma Ata in
1978 (World Health Organisation and United Nations Children
Fund, 1978). Along with the push to ensure access to these
medicines, came a realisation that recipients may not wish to use
the drugs, or may use them in ways other than those deﬁned
within biomedical practice. The push for the rational use of
medicines therefore emerged in parallel with the drive to increase
access (Podolsky, 2015). However, as described above, the
concept of rational medicines use has focused on behaviour of
individuals—patients, prescribers, farmers—and has not attended
to interconnections with wider changes in social, political and
economic structures and relations. These relations into which
antibiotics have become intertwined have largely been considered
the domain of other analyses, disciplines, policies—disconnected
from the materialities of antibiotics. However, in her clarion call
to attend to AMR, or witness ‘the end to modern medicine’,
Dame Sally Davies draws our attention to the threat AMR poses
to the whole apparatus of modern medicine. And one might
extend this argument to see these concerns as a response to a
threat to modernity itself.
The present moment of antimicrobial resistance as a major
topic of global concern can be understood to represent a moment
of inversion—when antimicrobials have been rendered visible
where previously they have been a part of the woodwork. In their
work on classiﬁcation systems as infrastructure, Bowker and Star
(2000) observe that good usable systems ‘disappear almost by
deﬁnition. The easier they are to use, the harder they are to see’
(p. 33). Such infrastructure comprises materials, information,
ordering. For example, the availability and usability of research
instruments and subjects shapes what science is constructed; the
supply chain, techniques and subject handling methods are
invented alongside biology’s conceptual frame. They argue that to
render such infrastructure visible ‘means learning to look closely
at technologies and arrangements that, by design and by habit,
tend to fade into the woodwork’ (p. 34). The idea of infrastructure
deﬁning what is possible follows Becker (1982) who observes how
infrastructure is deployed as ‘conventions and constraints’ such
that the length of musical concerts and sizes of paintings are set
within particular parameters. Inversion of the status quo is one
way that the woodwork may be rendered visible. An 8-foot
painting or 8-h musical would render visible the roles of parking
attendants, ticket takers, theatre rentals, the positioning of
paintings on walls, the size of rolls of canvas, the skills of
framers, the very doorways of museums and galleries. Thus, the
practice of inversion brings to the fore the arrangements of
objects, people and processes that may otherwise go unobserved
and yet shape possibilities for the ways things can be done and
conceived. The present awareness of antimicrobial resistance
appears to have produced an inversion whereby antimicrobials,
and their attendant relations and processes, have come to the
fore. This enables analyses of the possibilities, conventions and
constraints that have hitherto been taken for granted as common
sense, and the potential for reshaping these into the future.
There are numerous ways in which one might productively
explore this inversion of infrastructure presented by AMR. Here I
propose that analyses of antimicrobials as material, affective and
political infrastructures is valuable to an effort of rendering visible
the work of these medicines.
Material, affective and political infrastructures. What does the
threat of antimicrobial resistance draw our attention to in the
material infrastructural arrangements of domestic, health and
industrial settings? Historical work has highlighted the role of
hygiene and sanitation infrastructure in bringing about infection
control (Illich, 1976), on the tail of which antibiotics are also
understood to have enabled reductions in infectious diseases
(Headrick, 1981). To what extent antibiotics replaced or reshaped
the material infrastructure in maintaining disease control has
been less directly studied. Robert Bud draws our attention to the
dramatic increase in the number of beds on British medical wards
with the founding of the National Health Service in the mid
twentieth Century, when ‘the threats of cross-infection created by
this increased turnover were again managed by antibiotics’ (Bud,
2006, p. 197). The roles antibiotics now play in disease prevention
for surgery and chemotherapy, and the attendant concern about
the impact of drug resistant infection on the ability to carry out
these procedures and processes in the speedy and relatively
uncontained way they currently occur (Davies, 2013) suggests
that antibiotics have become part of the health infrastructure such
that they shape possibilities and constraints in pathways to health.
With rising concerns of antimicrobial resistance in humans,
relatively greater attention has been paid to the ways that anti-
biotics have been deployed to enable industrialisation of agri-
culture, particularly in livestock. Nonetheless, such investigation
is often cut short by the ‘multi-sectoral challenge’ of the
requirement for national productivity often contingent upon
agricultural production. Antibiotics are therefore switched-in for
biosecurity measures that attempt to prevent and contain infec-
tion whilst maintaining intensive farming. Such measures build
on the same tenets of standardisation of material as antibiotics
allow, rather than folding in diversity (Hinchliffe and Ward,
2014). Attention to antibiotics as material infrastructure, and the
inversion posed by AMR if these substances were to be removed,
prompts further questioning of how materials are currently
arranged and entangled with antibiotics.
Bringing to the fore antibiotics as affective infrastructure allows
for analyses of the ways in which these substances enable and
deﬁne relations—between people, organisations, countries and so
on. One of the most obvious relations that AMR has brought to
the fore is that of patients and prescribers—allowing us to see
how these medicines have themselves become a form of care, such
that in the absence of one medicine, providers often feel
compelled to prescribe another (Chandler et al., 2017; Hopkins
et al., 2017). Antibiotics have also shaped relations to biomedical
institutions—such that with AMR, hospitals may be transformed
from being seen as lighthouses of therapeutic modernity to
hothouses of infection (Gradmann, 2017). They also allow us to
understand what is at stake in the absence of an antimicrobial
prescription—which renders visible relations with work places,
expectations of productivity and the ways that antimicrobial
prescriptions have been legitimising illness and providing space
for recovery. An exercise to explore this further might be to
follow the impact of prescribing ‘rest’ in lieu of an antimicrobial
—and to thereby explicate the layers of social and economic
systems that make returning to work an imperative. Such an
inversion has been recently proposed by physicians observing a
problem of presenteeism amongst health care workers which
propogates disease in hospital environments, caused by sick leave
policies and the value placed on ‘selﬂess-acts’ of continuing to
work whilst ill (Chow and Mermel, 2018). And whilst
antimicrobials may allow for humans to become shaped into
more reliable and productive units of labour, they can also be
understood to enable animals to become more reliably produc-
tive, as well as to become more standardised units of production.
Thus, it is instructive to explore the pharmaceuticalisation of
PALGRAVE COMMUNICATIONS | https://doi.org/10.1057/s41599-019-0263-4 ARTICLE
PALGRAVE COMMUNICATIONS |            (2019) 5:53 | https://doi.org/10.1057/s41599-019-0263-4 | www.nature.com/palcomms 9
labour through antibiotics. In a similar vein, the economic
concerns about the impact of AMR on the workforce indicate a
concern over the potential slowing down of life. We become
aware that antibiotics enable the current tempo of life—indexed
to productivity and consumption, and entwined as much with
moral as ﬁnancial economies. Standardisation and scale also
become a part of this story, as we trace how antibiotics have
become part of the apparatus of global standards—as interfacing
objects that enable exchange of things or ideas to occur—we
become able to envision the wider imperatives at play in the
systems into which antibiotics have become a lynchpin. Empirical
research that seeks out the ways in which antibiotics are
entangled with these values of tempo, production, standardisation
and scale will be valuable in explicating the ways these substances
form relational infrastructure across the globe today.
The exploration of the roles of antibiotics as affective
infrastructure also opens-up for analysis the ways they make
possible particular political-economic values in the context and
drivers of urbanisation and globalisation. They enable, for
example, the revisiting of medicalisation—the encroachment of
biomedicine into areas hitherto conceived as outside of the
medical domain. The process of medicalisation can be understood
to have been shaped by values and social policy established in the
Enlightenment period of 17th–18th Century, principally ‘faith in
the progress and perfectibility of society with the help of science
and technology’ (Risse, 1992, p. 150). For Enlightenment
medicine, a key objective was ‘the displacement of such
pessimistic concepts of sickness for more hopeful outlooks
enshrined within new biomedical models of health and disease.
Fatalism and ignorance in health-related matters had to be
overcome’ (ibid, p. 154). While at this time, the focal point of
medicalisation was the professional expert who could deal with
health-related problems, and more recently pharmaceuticals have
been observed to take their place (Samsky, 2015), the framing of
hope of a disease-free humanity remains integral to biomedicine
today. In their history of acute bronchitis (cough) management in
Britain through the twentieth Century, Macfarlane and Worboys
(2007) illustrate how antibiotics enabled particular values in
human productivity to develop, allowed for a more medicines-as-
prevention strand to develop within healthcare, as well as how
antibiotics became entangled with the ways the pharmaceutical
industry could engage with a nationalising health system. Thus
one can unpack the roles of antibiotics in co-producing our
modern political economies, but also one can see how these
political economic values have become part of how we under-
stand and talk about antibiotics, and resistance, mobilised in
metaphors of war (Nerlich, 2009), interchangeably with migration
(Brown and Nettleton, 2017), capitalism (Brown and Nettleton,
2018) and entangled in the project of modernism itself
(Hutchison et al., 2018). Thus, following Dewey (1927) and
Collier et al. (2017), understanding antibiotics as infrastructure in
these ways enables us to ask what sorts of publics, collectives,
social forms and systems are brought into being by these
substances?
Conclusion
In this paper I have drawn attention to the framing of AMR
discourse and its consequences. I have argued that AMR has been
less easy to advocate for with an ‘actuarial’ approach and instead
support has been galvanised in its formulation as a threat,
through a ‘sentinel’ approach (following Lakoff, 2015). I have
drawn attention to the disconnect between the conﬁguration of
AMR as a problem of connectedness through a One Health fra-
mework, and approaches to implementation that most often
target individual behavioural change. These observations allow us
to explore what happens if we use different models to envision
AMR which are less speculative and more actuarial? And what
happens if we take seriously ‘one-health’ as a mode of governance
as well as a way of understanding the problem, or if we seek to
dis-embed antibiotic dependence from within neoliberal society? I
propose that to explore antibiotics as infrastructure resists the
micro/macro division implied in existing discourse, rather oper-
ating in a mode of entanglement. AMR presents an inversion of
the current status quo of biomedicine and beyond, rendering
visible in this moment the ways in which our lives are contingent
upon antimicrobial medicines: to deﬁne and deliver health care;
to enable productivity of work forces, industrialisation of food
other commodities; as well as making possible particular social
and political values in the context of modernisation, urbanisation
and globalisation. In this sense, antimicrobials can be considered
as infrastructure—as usable systems that disappear unless delib-
erately explicated. This opens-up possibilities for reconﬁguring
AMR research and action by shifting the focus of attention across
scales and enabling different forms of care, and different publics,
to come into view. Such shifts enable us to conceive of AMR not
only as ‘The End of Modern Medicine’ but as an invitation to an
era of medicine beyond that deﬁned through modernity.
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